Brown Advisory Inc Sage Therapeutics, Inc. Transaction History

Brown Advisory Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 12, 2019	SELL	$157.85 - $183.09 $1.15 Million - $1.33 Million	-7,288 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$89.33 - $163.65 $228,863 - $419,271	2,562 Added 54.21%	7,288 $1.16 Million
Q4 2018 Feb 13, 2019	BUY	$81.94 - $139.71 $141,428 - $241,139	1,726 Added 57.53%	4,726 $453,000
Q2 2018 Aug 10, 2018	SELL	$140.36 - $175.76 $17,685 - $22,145	-126 Reduced 4.03%	3,000 $470,000
Q1 2018 Jun 28, 2018	BUY	$152.15 - $192.33 $475,620 - $601,223	3,126 New	3,126 $503,000
Q1 2018 May 14, 2018	SELL	$152.15 - $192.33 $477,751 - $603,916	-3,140 Closed	0 $0
Q4 2017 Feb 12, 2018	BUY	$60.72 - $167.34 $190,660 - $525,447	3,140 New	3,140 $517,000
Q3 2017 Nov 13, 2017	SELL	$61.4 - $88.52 $191,015 - $275,385	-3,111 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	3,111	3,111 $248,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $326M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.